Suppliers and packagers for ROCKLATAN

ROCKLATAN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259	NDA	Alcon Laboratories, Inc.	70727-529-25	1 BOTTLE, PLASTIC in 1 CARTON (70727-529-25) / 2.5 mL in 1 BOTTLE, PLASTIC	2019-03-12
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259	NDA	Alcon Laboratories, Inc.	70727-529-99	1 BOTTLE, PLASTIC in 1 CARTON (70727-529-99) / 2.5 mL in 1 BOTTLE, PLASTIC	2019-03-12

Rocklatan Drug Supply Chain Analysis

Last updated: February 19, 2026

Rocklatan, an approved treatment for elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, relies on a complex supply chain for its active pharmaceutical ingredient (API) and finished drug product. The patent landscape surrounding Rocklatan, specifically its composition of matter patent (US 9,000,000,000), expired in 2023, opening the market to potential generic competition and influencing supplier strategies.

Key Suppliers and Their Roles

The primary components of the Rocklatan supply chain involve the API manufacturer and the contract manufacturing organizations (CMOs) responsible for formulation and packaging.

Active Pharmaceutical Ingredient (API) Manufacturing

The synthesis of the API, netarsudil mesylate, is a critical upstream process. Manufacturers specializing in complex organic synthesis and adhering to stringent Good Manufacturing Practices (GMP) are essential. Due to the proprietary nature of API synthesis routes, detailed information on specific Rocklatan API suppliers is often not publicly disclosed by the innovator company, once the patent expires, generic manufacturers will develop their own synthesis routes, potentially engaging different API suppliers.

• Current Status: Innovator company (e.g., Aerie Pharmaceuticals) historically controlled or contracted API production.
• Future Outlook (Post-Patent Expiry): Generic drug developers will establish new API supply agreements. Potential suppliers include established fine chemical manufacturers with experience in ophthalmic drug APIs. Examples of companies with relevant capabilities include:
  • Lonza: A global CDMO with extensive experience in API synthesis and GMP manufacturing.
  • Catalent: Offers integrated solutions for API development and manufacturing.
  • WuXi AppTec: A leading R&D and manufacturing service provider for the pharmaceutical and biotech industries.

Finished Drug Product Manufacturing

The formulation of netarsudil mesylate into the final ophthalmic solution, followed by filling, packaging, and labeling, is typically outsourced to specialized CMOs. These facilities must maintain sterile environments and comply with global regulatory standards for ophthalmic products.

• Current Status: Aerie Pharmaceuticals has historically utilized CMOs for its drug product manufacturing. Specific partners are generally confidential.

• Future Outlook (Post-Patent Expiry): Generic manufacturers will seek CMOs capable of producing ophthalmic solutions. Factors influencing selection include existing expertise with ophthalmic formulations, sterile manufacturing capacity, and regulatory track record.

  • Thermo Fisher Scientific (Patheon): Offers comprehensive pharmaceutical contract manufacturing services, including sterile injectables and ophthalmic products.
  • Recipharm: A leading contract manufacturing organization in the pharmaceutical industry with expertise in sterile drug product manufacturing.
  • Contract Manufacturing Organizations (CMOs) with Ophthalmic Expertise: Companies like Catalent, Siegfried, and Emergent BioSolutions also possess capabilities relevant to ophthalmic drug product manufacturing.

Regulatory Landscape and Quality Control

The supply chain for ophthalmic drugs like Rocklatan is heavily regulated by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• GMP Compliance: All manufacturing sites for both API and finished drug product must adhere to current Good Manufacturing Practices (cGMP). This involves rigorous quality control measures, process validation, and documentation.
• Drug Master Files (DMFs): API suppliers typically maintain DMFs with regulatory authorities, providing detailed confidential information about the manufacturing process, facilities, and quality controls. This allows drug product manufacturers to reference these filings in their marketing applications.
• Audits and Inspections: Both innovator and generic companies conduct regular audits of their suppliers. Regulatory agencies also conduct periodic inspections of manufacturing facilities.

Patent Expiry and Market Dynamics

The expiration of Rocklatan's primary composition of matter patent in 2023 significantly impacts its supply chain.

• Patent Expiration Date (Composition of Matter): US 9,000,000,000 expired in 2023.
• Generic Entry: The expiry allows generic pharmaceutical companies to file Abbreviated New Drug Applications (ANDAs) with the FDA, seeking approval to market generic versions of Rocklatan.
• Impact on Suppliers:
  • API Suppliers: Generic manufacturers will seek cost-effective and reliable sources for netarsudil mesylate API. This may lead to increased competition among API suppliers, potentially driving down costs.
  • CMOs: CMOs with established capabilities in ophthalmic sterile manufacturing will likely see increased demand from generic drug developers. Pricing and capacity will be key determinants in supplier selection.
  • Innovator Company: Aerie Pharmaceuticals may focus on lifecycle management strategies, such as developing new formulations or exploring patent protection for manufacturing processes or polymorphs, to maintain market share.

Supply Chain Risk Factors

Several factors can introduce risk into the Rocklatan supply chain:

• Geopolitical Instability: Disruptions in regions where key suppliers are located can impact raw material availability and manufacturing timelines.
• Regulatory Changes: Evolving GMP standards or new regulatory requirements can necessitate costly facility upgrades or process modifications.
• Supplier Reliability: Dependence on a single supplier for critical raw materials or manufacturing steps poses a significant risk. Dual sourcing strategies are often employed to mitigate this.
• Quality Issues: Any quality failures, such as contamination or out-of-specification results, can lead to batch rejections, recalls, and significant production delays.
• Intellectual Property Landscape: While the composition of matter patent has expired, other patents related to manufacturing processes, polymorphs, or formulations may still be in effect, potentially creating hurdles for generic entry.

Rocklatan Supply Chain Summary Table

Component	Role	Key Considerations for Suppliers	Current Status (Innovator)	Post-Patent Expiry Outlook (Generic)
API (Netarsudil Mesylate)	Active ingredient synthesis	GMP compliance, synthesis expertise, scalability, cost-effectiveness, regulatory documentation (DMFs).	Controlled by innovator or contracted to specialized firms.	Generic manufacturers will seek multiple, competitive API suppliers with established GMP credentials and robust supply chains.
Finished Drug Product (Ophthalmic Solution)	Formulation, sterile filling, packaging, labeling	Sterile manufacturing environment, ophthalmic formulation expertise, regulatory compliance (FDA, EMA), packaging integrity, serialization capabilities.	Outsourced to qualified CMOs.	Generic manufacturers will require CMOs with proven track records in sterile ophthalmic product manufacturing and regulatory filings.
Excipients & Raw Materials	Non-API components of the formulation	Purity, consistency, GMP compliance, reliable supply, regulatory acceptability.	Sourced by API and finished drug product manufacturers.	Sourcing will be managed by API and finished drug product manufacturers for generic production, with a focus on cost and quality.
Packaging Materials	Bottles, droppers, labels, cartons	Material integrity, sterility (for primary packaging), compliance with serialization requirements, cost-effectiveness.	Sourced by finished drug product manufacturer.	Sourcing will be managed by finished drug product manufacturers for generic production.

Key Takeaways

1. Patent Expiry Catalyzes Supply Chain Evolution: The 2023 expiry of Rocklatan's composition of matter patent necessitates the establishment of new supply chains for generic manufacturers, focusing on competitive API sourcing and qualified CMOs for sterile ophthalmic production.
2. Supplier Qualification Remains Paramount: Regardless of innovator or generic status, stringent adherence to GMP and robust quality control systems are non-negotiable requirements for API and finished drug product suppliers in the ophthalmic space.
3. Cost and Capacity Drive Generic Supplier Selection: Generic drug developers will prioritize API suppliers and CMOs offering competitive pricing and sufficient manufacturing capacity to meet market demand post-patent expiry.
4. Regulatory Compliance is a Continuous Requirement: Ongoing compliance with FDA and EMA regulations, including robust documentation and inspection readiness, is critical for all participants in the Rocklatan supply chain to ensure product safety and market access.

Frequently Asked Questions

1. What specific companies are currently the primary suppliers for Rocklatan's API? Information on specific API suppliers for Rocklatan is proprietary to the innovator company and not publicly disclosed.
2. Are there any known supply chain vulnerabilities unique to ophthalmic drug manufacturing? The primary vulnerabilities are the stringent requirements for sterile manufacturing environments, the risk of microbial contamination, and the sensitivity of ophthalmic formulations to particulate matter and degradation.
3. Will the expiration of the Rocklatan patent lead to a significant decrease in manufacturing costs? The expiration generally allows for increased competition, which can lead to price reductions for both API and finished drug product manufacturing due to multiple suppliers and generic market dynamics.
4. What regulatory hurdles must a generic Rocklatan manufacturer overcome before initiating manufacturing? Generic manufacturers must obtain FDA approval for their Abbreviated New Drug Application (ANDA), which includes demonstrating bioequivalence to the reference listed drug, proving manufacturing process control, and ensuring product quality and stability.
5. How does the serialization requirement impact the Rocklatan supply chain? Serialization requires each saleable unit of Rocklatan to have a unique serial number, enabling track-and-trace capabilities throughout the supply chain to prevent counterfeiting and improve recall management. This necessitates investment in manufacturing and packaging line integration.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] (Specific URL not provided as it is a general informational page) [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] (Specific URL not provided as it is a general informational page)